Cynata Therapeutics completes Phase 1 trial patient enrolment

Cynata Therapeutics Limited (ASX: $CYP) has successfully completed patient enrolment in its Phase 1 clinical trial of CYP-006TK, a topical wound dressing product candidate, for the treatment of diabetic foot ulcers (DFU). The trial, which involves 30 patients with DFU, aims to investigate the potential of CYP-006TK in promoting wound healing in this patient population. The last patient visit in this trial is expected to occur around September 2024.

Executive Commentary on Patient Enrolment Completion

We are delighted to have completed enrolment, and we extend our thanks to all of the investigators, study staff and patients for helping us to achieve this milestone. We recently announced very encouraging initial data from the first 16 patients enrolled in this trial after 10 weeks' follow-up, with a median percentage reduction in wound surface area of 87.6% in the active CYP-006TK group, compared to 51.1% in the control group. We now look forward to completing the follow-up period and releasing the full results from this study shortly thereafter. - Dr Jolanta Airey MD, Cynata's Chief Medical Officer

Summary of Cynata Therapeutics' Phase 1 Trial Completion

Cynata Therapeutics (ASX: $CYP) has achieved a significant milestone by completing patient enrolment in its Phase 1 clinical trial of CYP-006TK for the treatment of diabetic foot ulcers. The trial, which has reached its pre-specified sample size of 30 patients with DFU, aims to assess the potential of CYP-006TK in promoting wound healing. Initial data from the trial has shown promising results, with a median percentage reduction in wound surface area of 87.6% in the active CYP-006TK group, compared to 51.1% in the control group. The company looks forward to releasing the full results from this study shortly after completing the follow-up period, which is expected to occur around September 2024. Cynata Therapeutics continues to focus on the development of therapies based on its proprietary Cymerus™ stem cell platform technology, with ongoing trials in various medical conditions, including graft-versus-host disease, osteoarthritis, and diabetic foot ulcers.